BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 34433584)

  • 21. The effect of sodium butyrate and cisplatin on expression of EMT markers.
    Mrkvicova A; Chmelarova M; Peterova E; Havelek R; Baranova I; Kazimirova P; Rudolf E; Rezacova M
    PLoS One; 2019; 14(1):e0210889. PubMed ID: 30653577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors.
    Su Y; Hopfinger NR; Nguyen TD; Pogash TJ; Santucci-Pereira J; Russo J
    J Exp Clin Cancer Res; 2018 Dec; 37(1):314. PubMed ID: 30547810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.
    Li X; Yu J; Brock MV; Tao Q; Herman JG; Liang P; Guo M
    Oncotarget; 2015 May; 6(13):11547-60. PubMed ID: 25909168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance.
    Staub J; Chien J; Pan Y; Qian X; Narita K; Aletti G; Scheerer M; Roberts LR; Molina J; Shridhar V
    Oncogene; 2007 Jul; 26(34):4969-78. PubMed ID: 17310998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ARID1A-mutated ovarian cancers depend on HDAC6 activity.
    Bitler BG; Wu S; Park PH; Hai Y; Aird KM; Wang Y; Zhai Y; Kossenkov AV; Vara-Ailor A; Rauscher FJ; Zou W; Speicher DW; Huntsman DG; Conejo-Garcia JR; Cho KR; Christianson DW; Zhang R
    Nat Cell Biol; 2017 Aug; 19(8):962-973. PubMed ID: 28737768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists.
    Mossman D; Kim KT; Scott RJ
    BMC Cancer; 2010 Jul; 10():366. PubMed ID: 20618997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiproliferative Effects of Epigenetic Modifier Drugs Through E-cadherin Up-regulation in Liver Cancer Cell Lines.
    Uribe D; Cardona A; Esposti DD; Cros MP; Cuenin C; Herceg Z; Camargo M; Cortés-Mancera FM
    Ann Hepatol; 2018; 17(3):444-460. PubMed ID: 29735783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of Epigenetic Drug Targeting of Heterogenous Tumor Cell Fractions Using Potential Biomarkers of Response in Ovarian Cancer.
    Singh AK; Chandra N; Bapat SA
    Clin Cancer Res; 2015 Nov; 21(22):5151-63. PubMed ID: 26130461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
    Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
    [No Abstract]   [Full Text] [Related]  

  • 30. DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.
    Bruyer A; Maes K; Herviou L; Kassambara A; Seckinger A; Cartron G; Rème T; Robert N; Requirand G; Boireau S; Müller-Tidow C; Veyrune JL; Vincent L; Bouhya S; Goldschmidt H; Vanderkerken K; Hose D; Klein B; De Bruyne E; Moreaux J
    Br J Cancer; 2018 Apr; 118(8):1062-1073. PubMed ID: 29500406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP].
    Meng CF; Dai DQ; Guo KJ
    Ai Zheng; 2008 Dec; 27(12):1251-5. PubMed ID: 19079988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells.
    Heller G; Schmidt WM; Ziegler B; Holzer S; Müllauer L; Bilban M; Zielinski CC; Drach J; Zöchbauer-Müller S
    Cancer Res; 2008 Jan; 68(1):44-54. PubMed ID: 18172295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aberrant promoter methylation of SPARC in ovarian cancer.
    Socha MJ; Said N; Dai Y; Kwong J; Ramalingam P; Trieu V; Desai N; Mok SC; Motamed K
    Neoplasia; 2009 Feb; 11(2):126-35. PubMed ID: 19177197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Promoter hypermethylation influences the suppressive role of maternally expressed 3, a long non-coding RNA, in the development of epithelial ovarian cancer.
    Sheng X; Li J; Yang L; Chen Z; Zhao Q; Tan L; Zhou Y; Li J
    Oncol Rep; 2014 Jul; 32(1):277-85. PubMed ID: 24859196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic and epigenetic inactivation of T-cadherin in human hepatocellular carcinoma cells.
    Chan DW; Lee JM; Chan PC; Ng IO
    Int J Cancer; 2008 Sep; 123(5):1043-52. PubMed ID: 18553387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
    Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN
    Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of
    Halaburková A; Jendželovský R; Kovaľ J; Herceg Z; Fedoročko P; Ghantous A
    Clin Epigenetics; 2017; 9():62. PubMed ID: 28603560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2'-deoxycytidine on ovarian cancer.
    Meng F; Sun G; Zhong M; Yu Y; Brewer MA
    Br J Cancer; 2013 Feb; 108(3):579-86. PubMed ID: 23370212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo.
    Alcazar O; Achberger S; Aldrich W; Hu Z; Negrotto S; Saunthararajah Y; Triozzi P
    Int J Cancer; 2012 Jul; 131(1):18-29. PubMed ID: 21796622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.
    Wang Y; Chen SY; Colborne S; Lambert G; Shin CY; Santos ND; Orlando KA; Lang JD; Hendricks WPD; Bally MB; Karnezis AN; Hass R; Underhill TM; Morin GB; Trent JM; Weissman BE; Huntsman DG
    Mol Cancer Ther; 2018 Dec; 17(12):2767-2779. PubMed ID: 30232145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.